Bayer Watch 63E
Bayer, the pharmaceutical group, is nearing deals to resolve 50,000 to 85,000 of 125,000 U.S. cancer lawsuits over the use of its Roundup weedkiller
Share this:
Bayer, the pharmaceutical group, is nearing deals to resolve 50,000 to 85,000 of 125,000 U.S. cancer lawsuits over the use of its Roundup weedkiller, reported Bloomberg citing people familiar with the matter.
The settlements still need approval from the company’s supervisory board, in June.
Chris Loder, a U.S.-based spokesman for Bayer said “As we have said previously, the company will consider a resolution if it is financially reasonable and provides a process to resolve potential future litigation.”
From a technical perspective, the stock price has landed on a support at 55.3E (Lower Bollinger band + 50DMA) and is posting a rebound. The bullish gap opened above the 20DMA is a positive signal. However, the stock price remains stuck in trading range on a short term basis between 55.3E and 63E.
A breakout confirmation of 63E would confirm the bullish outlook with 68E as target.
Alternatively, a push below 55.3E would reinstate a bearish bias towards 50E.
Source: GAIN Capital, TradingView
Bayer, the pharmaceutical group, is nearing deals to resolve 50,000 to 85,000 of 125,000 U.S. cancer lawsuits over the use of its Roundup weedkiller, reported Bloomberg citing people familiar with the matter.
The settlements still need approval from the company’s supervisory board, in June.
Chris Loder, a U.S.-based spokesman for Bayer said “As we have said previously, the company will consider a resolution if it is financially reasonable and provides a process to resolve potential future litigation.”
From a technical perspective, the stock price has landed on a support at 55.3E (Lower Bollinger band + 50DMA) and is posting a rebound. The bullish gap opened above the 20DMA is a positive signal. However, the stock price remains stuck in trading range on a short term basis between 55.3E and 63E.
A breakout confirmation of 63E would confirm the bullish outlook with 68E as target.
Alternatively, a push below 55.3E would reinstate a bearish bias towards 50E.
Source: GAIN Capital, TradingView
Related tags:
Latest market news
The complete CFD trading experience
Award-winning platforms, competitive spreads, low commissions and dedicated support.
We live and breathe the markets and are dedicated to helping traders realise their ambitions as we continue to set the industry bar.
Economic calendar
Web Trader platform
Our sophisticated web-based platform is packed with features.
Related articles
USD/JPY Q4 2026 Outlook: Hawkish Fed Pricing Clashes With Intervention Risk
The year-end tug-of-war is clear: hawkish Fed pricing supports USD/JPY, while intervention risk limits the upside.
Japanese Yen Forecast: USD/JPY 4% Rally Challenges Post-Intervention Downtrend 9 24 2026
USD/JPY momentum has shifted sharply higher, putting a major resistance confluence in focus as U.S. and Japanese event risk builds.
GBP/USD, DJIA Outlook: Support Levels Meet Oversold Risks
GBP/USD and the Dow test key support levels as rising Treasury yields, Fed rate-hike expectations and oversold momentum increase reversal risks.
StoneX Europe Ltd may make third party material available on this website which may contain information included but not limited to the conditions of financial markets. The material is for information purposes only and does not contain, and should not be construed as containing, investment advice and/or investment recommendation and/or an investment research and/or an offer of or solicitation for any transactions in financial instruments; any decision to enter into a specific transaction shall be made by the client following an assessment by him/her of their situation.
StoneX Europe Ltd makes no representation or warranty and assumes no liability as to the accuracy or completeness of the information provided, nor any loss arising from any investment based on a recommendation, forecast or other information supplied. You should always seek independent advice as to your suitability to speculate in any related markets and your ability to assume the associated risks, if you are at all unsure. We are not under any obligation to update any such material. Any opinion made may be personal to the author and may not reflect the opinion of StoneX Europe Ltd.